Yann Mikaeloff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yann Mikaeloff has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
A. Roussot
Department of Biostatistics and Bioinformatics (DIM), CHU Dijon, France
1 shared publicationAdrien Roussot
Biostatistics and Bioinformatics (DIM), University Hospital, Dijon, France
1 shared publication- Alain Weill
EPI‐PHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products [ANSM] French National Health Insurance [CNAM]) Saint‐Denis France
1 shared publication Amine Benyamina
Université Paris Saclay, UR PSYCOMADD, Hôpital Universitaire Paul Brousse (AP-HP), France
1 shared publication- Anne-Sophie Mariet
Service de Biostatistiques et d’Information Médicale, Centre Hospitalier Universitaire Dijon Bourgogne, Université Bourgogne Europe, 21000 Dijon, France
1 shared publication B. Falissard
12 Université Paris-Saclay, UVSQ, Inserm, Developmental Psychiatry, CESP, Villejuif, France
1 shared publication
Latest Publications
- Open Access
- 13 June 2022
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 65 (1) , 1-30
Prolonged impact of the COVID-19 pandemic on self-harm hospitalizations in France: A nationwide retrospective observational study
Background: The first wave of the COVID-19 pandemic in France was associated with a reduced number of hospitalizations for self-harm, with the exception of older people. The on-going pandemic may have both sustained and delayed effects.Methods: Data were extracted from the French national hospital database (PMSI), a nationwide exhaustive database. The number of self-harm hospitalizations (ICD-10 codes X60–84) between September 1, 2020 and August 31, 2021 (N = 85,679) was compared to 2019 (N = 88,782) using Poisson regression models.Results: There was a decrease in the total number of self-harm hospitalizations during the studied period versus 2019 (−3.5%; Relative Risk [RR] [95% Confidence Intervals] = 0.97 [0.96–0.97]; p < 0.0001). However, sex and age effects were identified. While adults aged 30–59-years-old showed a decrease (monthly decreases: −12.6 to −15.0%), we found an increase in adolescent girls (+27.7%, RR = 1.28 [1.25–1.31]; p < 0.0001), notably since January 2021. Moreover, the numbers were similar to 2019 in adolescent boys, in youths aged 20–29 years, and in people aged 70 and more. Hospitalizations in intensive care units decreased (−6.7%, RR = 0.93 [0.91–0.96]; p < 0.0001) and deaths at hospital following self-harm remained stable (+0.6%, Hazard Ratio = 0.99 [0.91–1.08], p = 0.79).Conclusions: During this second stage, the number of self-harm hospitalizations remained at a lower level than in the prepandemic period. However, significant variations over time, age, and sex were observed. Young people (notably adolescent girls) appear to have particularly suffered from the persistence of the pandemic, while older people did not show any decrease since the beginning. Vigilance and continuing prevention are warranted.
- 13 June 2022
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 65 (1) , 1-30
Open AccessProlonged impact of the COVID-19 pandemic on self-harm hospitalizations in France: A nationwide retrospective observational study
Background: The first wave of the COVID-19 pandemic in France was associated with a reduced number of hospitalizations for self-harm, with the exception of older people. The on-going pandemic may have both sustained and delayed effects.Methods: Data were extracted from the French national hospital database (PMSI), a nationwide exhaustive database. The number of self-harm hospitalizations (ICD-10 codes X60–84) between September 1, 2020 and August 31, 2021 (N = 85,679) was compared to 2019 (N = 88,782) using Poisson regression models.Results: There was a decrease in the total number of self-harm hospitalizations during the studied period versus 2019 (−3.5%; Relative Risk [RR] [95% Confidence Intervals] = 0.97 [0.96–0.97]; p < 0.0001). However, sex and age effects were identified. While adults aged 30–59-years-old showed a decrease (monthly decreases: −12.6 to −15.0%), we found an increase in adolescent girls (+27.7%, RR = 1.28 [1.25–1.31]; p < 0.0001), notably since January 2021. Moreover, the numbers were similar to 2019 in adolescent boys, in youths aged 20–29 years, and in people aged 70 and more. Hospitalizations in intensive care units decreased (−6.7%, RR = 0.93 [0.91–0.96]; p < 0.0001) and deaths at hospital following self-harm remained stable (+0.6%, Hazard Ratio = 0.99 [0.91–1.08], p = 0.79).Conclusions: During this second stage, the number of self-harm hospitalizations remained at a lower level than in the prepandemic period. However, significant variations over time, age, and sex were observed. Young people (notably adolescent girls) appear to have particularly suffered from the persistence of the pandemic, while older people did not show any decrease since the beginning. Vigilance and continuing prevention are warranted.
- Open Access
- 1 November 2021
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 228, 109062
Effects of the 2020 health crisis on acute alcohol intoxication: A nationwide retrospective observational study
- 1 November 2021
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 228, 109062
Open AccessEffects of the 2020 health crisis on acute alcohol intoxication: A nationwide retrospective observational study
- 19 May 2020
- Published by Wolters Kluwer Health in Neurology
- Vol. 94 (20) , e2168-e2179
Seasonal influenza vaccine and Guillain-Barré syndrome
Objective To evaluate the risk of Guillain-Barré syndrome (GBS) following seasonal influenza vaccination based on French nationwide data. Methods All cases of GBS occurring in metropolitan France between September 1 and March 31 from 2010 to 2014 were identified from the French national health data system. Data were analyzed according to the self-controlled case series method. The risk period started 1 day after the patient received vaccine (D1) until 42 days after vaccination (D42). The incidence of GBS during this risk period was compared to that of the control period (D43–March 31). The incidence rate ratio (IRR) was estimated after adjusting for seasonality and presence or not of acute infections. Results Between September and March, of the 2010/2011 to 2013/2014 influenza vaccination seasons, 3,523 cases of GBS occurred in metropolitan France and were included in the study. Among them, 15% (527 patients) had received influenza vaccination. A total of 140 patients developed GBS during the 42 days following influenza vaccination. The crude risk of developing GBS was not significantly increased during the 42 days following influenza vaccination (IRR, 1.02; 95% confidence interval [CI], 0.83–1.25; p = 0.85). This result remained nonsignificant after adjustment for calendar months and the incidence of acute gastrointestinal and respiratory tract infections (IRR, 1.10; 95% CI, 0.89–1.37; p = 0.38). In contrast, the risk of GBS was fourfold higher after acute respiratory tract infection (IRR, 3.89; 95% CI, 3.52–4.30; p < 0.0001) or gastrointestinal infection (IRR, 3.64; 95% CI, 3.01–4.40; p < 0.0001). Conclusions No association between seasonal influenza vaccination and GBS was shown during the 42 days following vaccination.
- 19 May 2020
- Published by Wolters Kluwer Health in Neurology
- Vol. 94 (20) , e2168-e2179
Seasonal influenza vaccine and Guillain-Barré syndrome
Objective To evaluate the risk of Guillain-Barré syndrome (GBS) following seasonal influenza vaccination based on French nationwide data. Methods All cases of GBS occurring in metropolitan France between September 1 and March 31 from 2010 to 2014 were identified from the French national health data system. Data were analyzed according to the self-controlled case series method. The risk period started 1 day after the patient received vaccine (D1) until 42 days after vaccination (D42). The incidence of GBS during this risk period was compared to that of the control period (D43–March 31). The incidence rate ratio (IRR) was estimated after adjusting for seasonality and presence or not of acute infections. Results Between September and March, of the 2010/2011 to 2013/2014 influenza vaccination seasons, 3,523 cases of GBS occurred in metropolitan France and were included in the study. Among them, 15% (527 patients) had received influenza vaccination. A total of 140 patients developed GBS during the 42 days following influenza vaccination. The crude risk of developing GBS was not significantly increased during the 42 days following influenza vaccination (IRR, 1.02; 95% confidence interval [CI], 0.83–1.25; p = 0.85). This result remained nonsignificant after adjustment for calendar months and the incidence of acute gastrointestinal and respiratory tract infections (IRR, 1.10; 95% CI, 0.89–1.37; p = 0.38). In contrast, the risk of GBS was fourfold higher after acute respiratory tract infection (IRR, 3.89; 95% CI, 3.52–4.30; p < 0.0001) or gastrointestinal infection (IRR, 3.64; 95% CI, 3.01–4.40; p < 0.0001). Conclusions No association between seasonal influenza vaccination and GBS was shown during the 42 days following vaccination.
- 1 September 2006
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 118 (3) , 1133-1139
Prognostic Factors for Early Severity in a Childhood Multiple Sclerosis Cohort
OBJECTIVE. The goal was to identify prognostic factors for an early severe course in a cohort of patients with childhood-onset multiple sclerosis, for the construction of a predictive tool. METHODS. The cohort consisted of 197 children from the French Kid Sclérose en Plaques neuropediatric cohort with relapsing/remitting multiple sclerosis beginning before the age of 16 years. Patients were included from 1990 to 2003. We used multivariate survival analysis (Cox model) to evaluate the prognostic value of clinical, MRI, and biological covariates at onset for the occurrence of a third attack or severe disability (“severity” outcome). RESULTS. The cohort was monitored for a mean of 5.5 ± 3.6 years. The “severity” outcome was recorded for 144 patients (73%). The risk of severity was higher for girls, for a time between the first and second attacks of 35% for the upper 2 quartiles. CONCLUSIONS. The clinical and MRI prognostic factors for early severity that were identified were used as the basis of a predictive tool, which will be validated in another cohort. This tool should make it possible to identify subgroups at risk of early severe disease and should facilitate therapeutic studies.
- 1 September 2006
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 118 (3) , 1133-1139
Prognostic Factors for Early Severity in a Childhood Multiple Sclerosis Cohort
OBJECTIVE. The goal was to identify prognostic factors for an early severe course in a cohort of patients with childhood-onset multiple sclerosis, for the construction of a predictive tool. METHODS. The cohort consisted of 197 children from the French Kid Sclérose en Plaques neuropediatric cohort with relapsing/remitting multiple sclerosis beginning before the age of 16 years. Patients were included from 1990 to 2003. We used multivariate survival analysis (Cox model) to evaluate the prognostic value of clinical, MRI, and biological covariates at onset for the occurrence of a third attack or severe disability (“severity” outcome). RESULTS. The cohort was monitored for a mean of 5.5 ± 3.6 years. The “severity” outcome was recorded for 144 patients (73%). The risk of severity was higher for girls, for a time between the first and second attacks of 35% for the upper 2 quartiles. CONCLUSIONS. The clinical and MRI prognostic factors for early severity that were identified were used as the basis of a predictive tool, which will be validated in another cohort. This tool should make it possible to identify subgroups at risk of early severe disease and should facilitate therapeutic studies.
- 1 December 2003
- Published by Elsevier in Journal de Pédiatrie et de Puériculture
- Vol. 16 (8) , 401-405
Sclérose en plaques chez l’enfant
- 1 December 2003
- Published by Elsevier in Journal de Pédiatrie et de Puériculture
- Vol. 16 (8) , 401-405
Sclérose en plaques chez l’enfant
- Open Access
- 1 May 1995
- Published by American Society for Microbiology in Journal of Virology
- Vol. 69 (5) , 2794-800
Constitutive activation of a variant of the env-mpl oncogene product by disulfide-linked homodimerization
The myeloproliferative leukemia retrovirus (MPLV) has the v-mpl cellular sequences transduced in frame with the deleted and rearranged Friend murine leukemia virus env gene. The resulting env-mpl fusion oncogene is responsible for an acute myeloproliferative disorder induced in mice by MPLV. v-mpl is a truncated form of the c-mpl gene which encodes the receptor for thrombopoietin. We investigated the contribution of the Env-Mpl extracellular domain in the constitutive activation of this truncated cytokine receptor and found that the rearrangement of the env sequences in the env-mpl fusion gene was not required for oncogenicity. A pathogenic variant, DEL3MPLV, was generated, which differs from MPLV by the deletions of 22 amino acids of the Env signal peptide, all of the mature Env sequences, and 18 N-terminal amino acids of the v-Mpl extracellular domain. The resulting del3-mpl oncogene product conserves in its extracellular region the first 12 amino acids of the Env signal sequence including a cysteine residue, and 25 amino acids of the v-Mpl. We show here that a mutation converting this cysteine to a glycine completely abolishes del3-mpl oncogenicity and that the del3-mpl oncogene product is constitutively activated by disulfide-linked homodimerization.
- 1 May 1995
- Published by American Society for Microbiology in Journal of Virology
- Vol. 69 (5) , 2794-800
Open AccessConstitutive activation of a variant of the env-mpl oncogene product by disulfide-linked homodimerization
The myeloproliferative leukemia retrovirus (MPLV) has the v-mpl cellular sequences transduced in frame with the deleted and rearranged Friend murine leukemia virus env gene. The resulting env-mpl fusion oncogene is responsible for an acute myeloproliferative disorder induced in mice by MPLV. v-mpl is a truncated form of the c-mpl gene which encodes the receptor for thrombopoietin. We investigated the contribution of the Env-Mpl extracellular domain in the constitutive activation of this truncated cytokine receptor and found that the rearrangement of the env sequences in the env-mpl fusion gene was not required for oncogenicity. A pathogenic variant, DEL3MPLV, was generated, which differs from MPLV by the deletions of 22 amino acids of the Env signal peptide, all of the mature Env sequences, and 18 N-terminal amino acids of the v-Mpl extracellular domain. The resulting del3-mpl oncogene product conserves in its extracellular region the first 12 amino acids of the Env signal sequence including a cysteine residue, and 25 amino acids of the v-Mpl. We show here that a mutation converting this cysteine to a glycine completely abolishes del3-mpl oncogenicity and that the del3-mpl oncogene product is constitutively activated by disulfide-linked homodimerization.